JP2025510790A - 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途 - Google Patents

精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途 Download PDF

Info

Publication number
JP2025510790A
JP2025510790A JP2024556474A JP2024556474A JP2025510790A JP 2025510790 A JP2025510790 A JP 2025510790A JP 2024556474 A JP2024556474 A JP 2024556474A JP 2024556474 A JP2024556474 A JP 2024556474A JP 2025510790 A JP2025510790 A JP 2025510790A
Authority
JP
Japan
Prior art keywords
disorder
disorders
methylone
anxiety
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510790A5 (https=
Inventor
ブレイク マンデル
ストグニュー，マーティン
ルイーズ シュミット，ジェニファー
ゼーリグ，マルクス
Original Assignee
トランセンド セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/074369 external-priority patent/WO2023015154A1/en
Application filed by トランセンド セラピューティクス，インコーポレイテッド filed Critical トランセンド セラピューティクス，インコーポレイテッド
Publication of JP2025510790A publication Critical patent/JP2025510790A/ja
Publication of JP2025510790A5 publication Critical patent/JP2025510790A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024556474A 2022-03-31 2023-02-02 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途 Pending JP2025510790A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263325757P 2022-03-31 2022-03-31
US63/325,757 2022-03-31
US202263328343P 2022-04-07 2022-04-07
US63/328,343 2022-04-07
USPCT/US2022/074369 2022-08-01
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US202363437000P 2023-01-04 2023-01-04
US63/437,000 2023-01-04
PCT/US2023/012196 WO2023191952A1 (en) 2022-03-31 2023-02-02 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (2)

Publication Number Publication Date
JP2025510790A true JP2025510790A (ja) 2025-04-15
JP2025510790A5 JP2025510790A5 (https=) 2026-02-05

Family

ID=88203364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556474A Pending JP2025510790A (ja) 2022-03-31 2023-02-02 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途

Country Status (10)

Country Link
EP (1) EP4499066A4 (https=)
JP (1) JP2025510790A (https=)
KR (1) KR20240165982A (https=)
CN (1) CN119095593A (https=)
AU (1) AU2023241546A1 (https=)
CA (1) CA3254727A1 (https=)
IL (1) IL315832A (https=)
MX (1) MX2024012095A (https=)
TW (1) TW202345789A (https=)
WO (1) WO2023191952A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379978A (zh) * 2022-10-20 2025-07-25 创见疗法股份有限公司 苯乙胺和卡西酮及其立体异构体与其前体的制备

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) * 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
EP2931291B1 (en) * 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) * 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) * 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
AU2022330718B2 (en) * 2021-08-20 2026-02-19 Pharmala Biotech Inc. Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Also Published As

Publication number Publication date
MX2024012095A (es) 2025-01-09
KR20240165982A (ko) 2024-11-25
IL315832A (en) 2024-11-01
CN119095593A (zh) 2024-12-06
WO2023191952A1 (en) 2023-10-05
CA3254727A1 (en) 2023-10-05
TW202345789A (zh) 2023-12-01
EP4499066A4 (en) 2026-02-18
AU2023241546A1 (en) 2024-10-17
EP4499066A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US11969407B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
JP2025510790A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途
US20050096395A1 (en) Methods of treating attention deficit/hyperactivity disorder (adhd)
US20250221957A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US20250332139A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120411A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
EP4724433A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40112015A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
RS66934B1 (sr) Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
JP2024538015A (ja) 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン
CA2846768A1 (en) Combinations comprising a s1p receptor modulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260128